Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

Biosimilars Canada welcomes the implementation of Quebec’s biosimilar policy

Biosimilars Canada today welcomed the release of the details of the Government of Quebec’s biosimilar switching policy, which will increase the use of biosimilar medicines under the Public Prescription Drug Insurance Plan and generate significant savings for the province.
Read more

Alberta adds Lovenox enoxaparin to biosimilar switching program

Effective July 1, 2021, patients covered by Alberta’s public drug plan who take Lovenox enoxaparin are required to switch to an enoxaparin biosimilar by January 10, 2022. All new patient starts for enoxaparin will be covered for a biosimilar.

Read more

B.C.’s biosimilars policy a turning point for private plans

B.C.’s biosimilar switching policy has had a profound impact on private drug plans in the province, according to TELUS Health claims data for private drug plans. 

Read more